U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa
U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process
Pharmaceutical Investing Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Pharmaceutical Investing Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa
Pharmaceutical Investing Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
Pharmaceutical Investing Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
Biotechnology Stocks on Investors' Radar — Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
CHARBONE Hydrogen and ABB Sign Agreement to Advance North American Green Hydrogen Production Facilities
CHARBONE Hydrogene et ABB signent une entente pour accelerer les usines de production d'hydrogene vert en Amerique du Nord
Global Nickel Mining Market Size Forecasted to Reach $100 Billion By 2034 as Demand for Electric Vehicles Rises
Cizzle Brands Corporation Schedules Second Fiscal Quarter 2025 Financial Results Webcast for Thursday, March 27, 2025 at 4:30 PM ET
